Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

Inclusion Criteria

• •Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed histologically or cytologically ;
• •Patients confirmed as ALK positive (FISH or Ventana IHC or RT-PCR, NGS) in previous written reports.Disease progression after continuing treatment with prior second-generation ALK-TKI resistance (allowing crizotinib resistance) (as per RECIST 1.1);
• •Maximum one chemotherapy is allowed;The interval between the last administration of second-generation ALK-TKI and the trial enrollment should be at least 7 days;
• •Gender: both male and female;Age: ≥18 years old;
• •physical status score was 0-2;
• •survival ≥3 months;
• •certain organ system functions (no blood transfusion or use of constituent blood within 14 days before test)；
• •Asymptomatic CNS metastases that do not require treatment with steroids or anticonvulsants;If there is CNS metastasis, radiotherapy can be performed first, and no progress can be made after ≥28 days.Meningeal disease was not included in the group;
• •Patients must have measurable lesions according to RECIST1.1 criteria;
• •Willing and able to follow the trial and follow-up procedures;
• •Able to understand the nature of the experiment and sign written informed consent voluntarily.